Enzymes of the thymidylate cycle as targets for chemotherapeutic agents: mechanisms of resistance.
This brief review should serve to indicate that it is possible to assess tumor sensitivity to antifolates using fresh human tissue in short-term culture. The assays described differ from general assays of tumor sensitivity, such as the clonogenic assay or assays that measure 3H-thymidine incorporation as an indicator of cell viability (32-34), in that the effect of a drug on a human specific target (dihydrofolate reductase) is measured. These specific assays also may prove to be extremely useful in the detection of acquired drug resistance and for new analog drug development. In a general sense, this type of assay may eventually also be useful for guiding and selecting treatment for individual patients with other drugs with known mechanisms of action. Knowledge of the basis of tumor resistance is essential to develop new approaches to treatment, such as the use of other folate analogs that may still be effective, and to devise ways in which to selectively inhibit tumor cell growth using new analogs (trimetrexate) and leucovorin.
Bertino
J R
JR
Sloan-Kettering Institute for Cancer Research, Department of Medicine, Memorial Hospital, New York, NY 10021.
Li
W W
WW
Lin
J
J
Trippett
T
T
Goker
E
E
Schweitzer
B
B
Banerjee
D
D
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000201:enzymology
D000964:Antimetabolites, Antineoplastic; D013940:Thymidylate Synthase